DGX Quest Diagnostics, Inc.
2,644
$138.42
$0.26
(0.19%)
| Watchers | 2,644 |
| 52-Wk Low | $119.59 |
| 52-Wk High | $145.58 |
| Market Cap | $15.38B |
| Volume | 569,562.00 |
| 52-Wk High | $145.58 |
| 52-Wk Low | $119.59 |
Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads ConferencePR Newswire • 3 days ago
Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference PR Newswire SECAUCUS...
Share to Feed
Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and...
Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI Quest Diagnostics to Acquire PathAI...
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024...
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease Quest Diagnostics Adds p-tau217 Blood Biomarker...
Alpine Woods Capital Investors LLC raised its holdings in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 2.1% during the fourth quarter, according to the company in its most recent Form...
On 4/5/24, Quest Diagnostics, Inc. (DGX), Chimera Investment Corp (CIM), and Sylvamo Corp (SLVM) will all trade ex-dividend for their respective upcoming dividends...
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome...
Quest Diagnostics (NYSE:DGX - Get Free Report) and Aclarion (NASDAQ:ACON - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on...